David Onder
Psychiatric/Mental Health · Canton, OHNPI 1952036923
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 80.0% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $22,875, more than ten times the $409 reported in 2022. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 432 payments — averaging $64.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$22K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$855
- AbbVie$748
- Teva Pharmaceuticals USA, Inc.$655
- Vanda Pharmaceuticals Inc.$569
- Otsuka America Pharmaceutical, Inc.$540
- plus $2K from 12 others
What the payments were for
- Consulting fees$6,89825%
- Speaking & faculty fees$10,35037%
- Travel & lodging$1,9397%
- Food & beverage$8,50831%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 122 | $22,171 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 42 | $855 |
| AbbVie | 75 | $748 |
| Teva Pharmaceuticals USA, Inc. | 48 | $655 |
| Vanda Pharmaceuticals Inc. | 22 | $569 |
| Otsuka America Pharmaceutical, Inc. | 22 | $540 |
| Johnson & Johnson | 30 | $524 |
| Neurocrine Biosciences, Inc. | 26 | $508 |
| Axsome Therapeutics, Inc. | 14 | $414 |
| Supernus Pharmaceuticals, Inc. | 8 | $251 |
| Lundbeck LLC | 10 | $189 |
| E.r. Squibb & Sons, L.L.C. | 1 | $82 |
| Almatica Pharma LLC | 4 | $66 |
| Tris Pharma Inc | 4 | $65 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,709 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 31 | $47,904 |
| VraylarCariprazine Hcl | 15 | $24,156 |
| CaplytaLumateperone Tosylate | 12 | $18,473 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $16,181 |
| AuvelityDextromethorphan Hbr/Bupropion | 23 | $13,787 |
| BelsomraSuvorexant | 23 | $9,916 |
| Aripiprazole | 84 | $5,298 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 50 | $4,463 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,346 |
| Lurasidone Hcl | 23 | $3,102 |
| Atomoxetine Hcl | 23 | $2,623 |
| Lisdexamfetamine Dimesylate | 14 | $2,315 |
| Methylphenidate Er (La)Methylphenidate Hcl | 13 | $1,956 |
| Oxcarbazepine | 44 | $1,492 |
| Hydroxyzine Hcl | 52 | $1,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $540 | $47,90431 claims |
| AbbVieVraylar | $748 | $24,15615 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $855 | $18,47312 claims |
| Alkermes, Inc.Lybalvi | $22,171 | $16,18111 claims |
| Axsome Therapeutics, Inc.Auvelity | $414 | $13,78723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Canton
- Tara DavisCanton$14K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.